Sulfur dioxide (SO₂)

Information and recommendations for paramedics and doctors at the site

- Before approaching the patient, the paramedics and doctors at the site must make sure that they do not risk exposing themselves to sulfur dioxide.
- Patients exposed only to sulfur dioxide gas do not pose a significant risk of secondary contamination. Patients whose clothing or skin is contaminated with liquid sulfur dioxide (boiling point –10°C, 14°F, respectively) can secondarily contaminate rescue and medical personnel by direct contact or through off-gassing sulfur dioxide.
- Sulfur dioxide gas is rapidly corrosive when it comes in contact with moist tissue such as the eyes, skin, and upper respiratory tract causing eye irritation, coughing, chest pain, dyspnea, and bronchoconstriction. Laryngospasm and signs of pulmonary edema (shortness of breath, cyanosis, expectoration, cough) may occur.
- There is no antidote to be administered to counteract the effects of sulfur dioxide. Treatment consists of supportive measures.

| 1. Substance information | Sulfur dioxide (SO ₂), CAS 7446-09-5 Synonyms: Sulfurous anhydride Sulfur dioxide is, at room temperature, a colorless, nonflammable gas with a pungent, irritating, sulfocating sulfur odor. Under pressure or at temperatures below -10° C (14° F), it is a clear liquid. Sulfur dioxide is soluble in water and forms sulfurous acid (H_2 SO ₃). Sulfur dioxide is used in ore and metal refining, chemical manufacturing, wood pulp treatment in paper manufacturing, extracting lubricating oils, as a preservative, fumigant, disinfectant, reducing agent, antioxidant in magnesium processing, bleaching agent, fungicide, insecticide, and as a food additive or preservative. |
|--------------------------|---|
| 2. Routes of exposure | |
| Inhalation | Most exposures occur by inhalation . Sulfur dioxide's odor and irritant properties generally provide adequate warning of hazardous concentrations; however, olfactory fatigue may occur. Asthmatic subjects may respond to concentrations below the odor threshold. Prolonged low-level exposure may result in olfactory fatigue and tolerance of its irritant effects. Sulfur dioxide is heavier than air and may cause asphyxiation in poorly ventilated, low-lying, or enclosed spaces. |
| Skin/eye contact | Direct contact with liquid sulfur dioxide or gas on wet or moist skin causes severe chemical burns, leading to cell death and ulceration. |
| Ingestion | Ingestion of sulfur dioxide is unlikely because it is a gas at room temperature. |
| 3. Acute health effects | |
| Respiratory | Exposure to low concentrations of sulfur dioxide usually causes sore throat, coughing, and bronchoconstriction. Rapid development of respiratory distress with chest pain, dyspnea, and laryngospasm and pulmonary edema may occur with inhalation of high concentrations of sulfur dioxide gas. Pulmonary injury may progress over several hours. After severe exposure, respiratory and cardiovascular failure may occur. |
| Dermal | Deep burns of the skin and mucous membranes may be caused by contact with concentrated sulfur dioxide; disfiguring scars may result. Contact with less concentrated sulfur dioxide gas can cause burning |

| D Z | |
|------------------------------|---|
| | pain, redness, inflammation, and blisters. Contact with liquid sulfur dioxide under pressure can result in frostbite. |
| Ocular | Low gas concentrations cause burning discomfort, spasmodic blinking or involuntary closing of the eyelids, redness, and tearing. Corneal burns may occur at high concentrations. |
| Dose-effect relationships | Dose-effect relationships are as follows: |
| Sulfur dioxide concentration | Effect |
| 0.5-2 ppm | - Pulmonary function changes in asthmatic subjects during exercise |
| 3-5 ppm | - Odor detection (some tolerance develops) |
| 8-20 ppm | - Throat and conjunctival irritation and lacrimation |
| 50-100 ppm | - Strong eye, throat, and lower respiratory tract irritation, tolerated for 30- |
| 50-100 ppm | 60 minutes |
| 400-500 ppm | - Lethal after 1 minute |
| 4. Actions | |
| Rescuer self-protection | In response situations that involve exposure to potentially unsafe levels of sulfur dioxide (see below), pressure-demand, self- contained breathing apparatus and chemical-protective clothing shall be worn. Patients exposed only to sulfur dioxide gas do not pose a significant risk |
| | of secondary contamination. Patients whose clothing or skin is contaminated with liquid sulfur dioxide can secondarily contaminate other people by direct contact or through off-gassing sulfur dioxide. |
| Patient recovery | Patients should be removed from the contaminated zone immediately. Patients who are unable to walk may be removed on backboards or stretchers; if these are not available, carefully remove/transport patients with appropriate action to a safe zone, taking into account your self- protection. Immediate priorities must follow the "A, B, C's " (Airway, Breathing, |
| Decentemination | Circulation) of resuscitation. Patients exposed only to sulfur dioxide gas who have no evidence of |
| Decontamination | skin or eye irritation do not need decontamination. All others require decontamination. Patients who are able and cooperative may assist with their own decontamination. If the exposure involved liquid sulfur dioxide and if clothing is contaminated, remove and double-bag the clothing. Assure that exposed or irritated eyes have been irrigated with plain water or saline for at least 20 minutes. If not, continue eye irrigation during other basic care and transport. |
| | Remove contact lenses if present and easily removable without |
| | additional trauma to the eye. |
| | Assure that exposed skin and hair have been flushed with plain water for at least 15 minutes. If not, continue flushing during other basic care and transport. Protect eyes during flushing of skin and hair. |
| Initial treatment | Therapy will be empiric; there is no antidote to be administered to counteract the effects of sulfur dioxide. |
| | The following measures are recommended if the exposure concentration is 8-20 ppm or greater (depending on time exposed), if symptoms, e. g. eye irritation or pulmonary symptoms have developed, or if no exposure concentration can be estimated but exposure has possibly occurred: |
| | Administration of oxygen Administration of 8 puffs of beclomethasone (800 μg beclomethasone dipropionate) from a metered dose inhaler. |
| | Patients with severe clinical respiratory symptoms (e.g. bronchospasms, stridor) should be treated as follows: a) Nebulization of adrenaline (epinephrine): 2 mg adrenaline (2 ml) with 3 ml NaCl 0.9% and inhale through a nebulizer mask. |
| Poviowod: 2022 | |

b) Administration of a ß2-selective adrenoceptor agonist, e.g., four strokes of terbutaline or salbutamol or fenoterol (one stroke usually contains 0.25 mg of terbutaline sulfate; or 0.1 mg of salbutamol; or 0.2 mg of fenoterol); this may be repeated once after 10 minutes. Alternatively, 2.5 mg salbutamol and 0.5 mg atrovent may be administered by nebulizer mask.

If inhalation is not possible, administration of terbutaline sulfate (0.25 mg to 0.5 mg) subcutaneously or salbutamol (0.2 mg to 0.4 mg over 15 minutes) intravenously.

c) Intravenous administration of 250 mg methylprednisolone (or equivalent steroid dose).

Patients with clinical signs of a toxic lung edema (e.g. foamy sputum, wet crackles) should be treated as follows:

- a) Start CPAP-therapy (Continuous Positive Airway Pressure Ventilation).
- b) Intravenous administration of 1000 mg methylprednisolone (or an equivalent steroid dose) is recommended.

Intubation of the trachea or an alternative airway management should be considered in cases of respiratory compromise. When the patient's condition precludes this, consider cricothyrotomy if equipped and trained to do so.

Note: Efficacy of corticosteroid administration has not yet been proven in controlled clinical studies.

Patients exposed to a concentration of 8-20 ppm or greater (depending on time exposed) and patients without available exposure measurements but suspected of being exposed to concentrations of 8-20 ppm or greater (depending on time exposed) should be transferred to a hospital/emergency department.

If sulfur dioxide have been in contact with the moist skin, chemical burns may result; treat as thermal burns: adequate fluid resuscitation and administration of analgesics, maintenance of the body temperature, covering of the burn with a sterile pad or clean sheet. Contact with liquid sulfur dioxide under pressure can result in frostbite.

After eye exposure chemical burns may result; treat as thermal burns. Immediately consult an ophthalmologist.

Note: Any facial exposure to liquid sulfur dioxide should be considered as a serious exposure.

Asymptomatic patients exposed to a concentration of less than 8-20 ppm (depending on the period of time exposed) as well as patients who have a normal clinical examination and no signs or symptoms of toxicity may be discharged after an appropriate observation period in the following circumstances:

- a) The evaluating physician is experienced in the evaluation of individuals with sulfur dioxide exposure.
- b) Information and recommendations for patients with follow-up instructions are provided verbally and in writing. Patients are advised to seek medical care promptly if symptoms develop or recur.
- c) The physician is comfortable that the patient understands the health effects of sulfur dioxide and the provided follow-up instructions.
- d) Site medical is notified, so that the patient may be contacted at regular intervals in the 24-hour period following release.
- e) Heavy physical work should be precluded for 24 hours.

Patient release/ follow-up instructions f) Exposure to cigarette smoke should be avoided for 72 hours; the smoke may worsen the condition of the lungs.

In this document BASF has made a diligent effort to ensure the accuracy and currency of the information presented but makes no claim that the document comprehensively addresses all possible situations related to this topic. This document is intended as an additional resource for paramedics and doctors at the site in assessing the condition and managing the treatment of patients exposed to sulfur dioxide. It is not, however, a substitute for the professional judgement of a paramedic or a doctor and must be interpreted in the light of specific information regarding the patient available to such a paramedic or doctor and in conjunction with other sources of authority.

BASF SE

Corporate Health Management Carl-Bosch-Straße 38 67056 Ludwigshafen Germany BASF Corporation Medical Department 100 Campus Drive, M/S F 221 Florham Park, NJ 07932 USA